[1] Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum, 1991, 34: 937-944. [2] ter Borg E J, Horst G, Hummel E J, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term,prospective study. Arthritis Rheum, 1990, 33: 634-643. [3] Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum,1982, 25: 1271-1277. [4] Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640. [5] Livneh A, Or G, Many A, et al. Anti-DNA antibodies secreted by peripheral B cells of lupus patients have both normal and lupusspecific features. Clin Immunol Immunopathol, 1993, 68: 68-73. [6] Miret C, Font J, Molina R, et al. Bcl-2 oncogene (B cell lymphoma/leukemia-2) levels correlate with systemic lupus erythematosus disease activity. Anticancer Res, 1999, 19: 3073-3076. [7] Jodo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.Clin Exp Immunol, 1997, 107: 89-95. [8] Radic MZ, Mackle J, Erikson J, et al. Residues that mediate DNA binding of autoimmune antibodies. J Immunol, 1993, 150: 4966-4977. [9] 康向东,陈顺乐,沈南,等.狼疮ds-DNA抗体VL基因的突变可能影响抗体的致病性中华风湿病学杂志,1999,3:14-16. [10] Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet, 1995, 345: 1595-1599. |